Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 99.75M P/E - EPS this Y 30.70% Ern Qtrly Grth -
Income -27.24M Forward P/E -4.66 EPS next Y 41.40% 50D Avg Chg 7.00%
Sales 1.55M PEG - EPS past 5Y - 200D Avg Chg -13.00%
Dividend N/A Price/Book 2.09 EPS next 5Y - 52W High Chg -48.00%
Recommedations 1.50 Quick Ratio 8.49 Shares Outstanding 27.86M 52W Low Chg 27.00%
Insider Own 65.17% ROA -39.85% Shares Float 7.56M Beta 1.38
Inst Own 28.63% ROE -67.37% Shares Shorted/Prior 9.35K/13.49K Price 3.59
Gross Margin - Profit Margin - Avg. Volume 18,341 Target Price 8.00
Oper. Margin -1,209.62% Earnings Date May 10 Volume 7,977 Change -7.71%
About Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Sol-Gel Technologies Ltd. News
04/01/24 Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
03/14/24 Sol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
06:00 AM Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
11/30/23 Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
11/28/23 Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
11/20/23 Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?
11/09/23 Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
10/31/23 Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies
10/30/23 3 Generic Drug Stocks to Watch Amid Improving Market Prospects
10/10/23 Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Invest In Growth?
08/30/23 Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
08/10/23 Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates
08/10/23 Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
07/21/23 Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Top Key Executive Moshe Arkin is the most upbeat insider, and their holdings increased by 15% last week
06/06/23 Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
06/02/23 Shareholders in Sol-Gel Technologies (NASDAQ:SLGL) are in the red if they invested five years ago
SLGL Chatroom

User Image LoyalShark Posted - 1 week ago

$SLGL Worth the read ... and worth the fight to end the NASDAQ's minimum bid bullshit that DESTROYS shareholders. We have to change this stupid rule. It simply feeds the shorts, dilutes shareholders and makes small and microcap companies in many markets uninvestible. The rule serves no purpose in todays markets. Might as well start here. Let me know what you all think of the $1 minimum bid rule. https://news.bloomberglaw.com/us-law-week/nasdaq-delisting-threat-is-tricky-for-companies-trading-below-1

User Image DarkSonar Posted - 04/30/24

$SLGL No volume. Wow

User Image DarkSonar Posted - 04/16/24

$SLGL This looks like is having a good day. Still no volume to be attractive

User Image weichsel1 Posted - 1 month ago

$SLGL Now trading at 65 percent of net cash on hand. (27m market cap, with a net 41m of cash on hand at last report.)

User Image DarkSonar Posted - 1 month ago

$SLGL What happened?

User Image CDCcsd Posted - 1 month ago

$SLGL Raymond James has it as Strong Buy1, cash enough to fund into 2026, PT $7.

User Image weichsel1 Posted - 1 month ago

$SLGL Any explanation for today's drastic drop? (Other than a very liquid market)

User Image DonCorleone77 Posted - 1 month ago

$SLGL $ARQT Sol-Gel Technologies collaboration partner first-to-file ANDA generic to Zoryve Sol-Gel Technologies (SLGL) announced that Padagis Israel Pharmaceuticals, Sol-Gel's collaboration partner, submitted a first-to-file Abbreviated New Drug Application, ANDA, to the U.S. Food and Drug Administration for Roflumilast Cream, 0.3%, a drug product generic to Zoryve Cream, indicated for the treatment of plaque psoriasis in patients six years of age and older. On March 26, 2024, Arcutis Biotherapeutics, Inc. (ARQT) initiated a patent infringement action in the U.S. District Court for the District of New Jersey regarding the Padagis Roflumilast Cream, 0.3% ANDA. "According to recent leading analysts' reports, Zoryve Cream is estimated to generate net revenue exceeding $500 million by the end of 2030. Submissions such as Padagis's Roflumilast Cream, 0.3% ANDA demonstrate the historic value of Sol-Gel's partnership with Padagis....."

User Image Stock_Titan Posted - 1 month ago

$SLGL Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream https://www.stocktitan.net/news/SLGL/sol-gel-s-collaboration-partner-first-to-file-anda-drug-product-quzskb3mjqz2.html

User Image weichsel1 Posted - 03/25/24

$SLGL Has this study been discussed here? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10939128/

User Image LoyalShark Posted - 03/20/24

$SLGL If Raymond James still loves them then so will I.

User Image CDCcsd Posted - 03/18/24

$SLGL Raymond James reaffirmed Strong Buy 1 rating on the stock. PT $7.

User Image ChiefOG Posted - 03/14/24

$SLGL 🧐

User Image LoyalShark Posted - 1 month ago

$SLGL Anyone have a read on what the analysts are saying about the earnings? Raymond James?

User Image epsguid Posted - 1 month ago

$SLGL reported a loss of $0.17, consensus was ($0.16) via @eWhispers #epsmiss http://eps.sh/d/slgl

User Image DonCorleone77 Posted - 1 month ago

$SLGL Sol-Gel Technologies sees cash runway into 2H25 As of December 31, 2023, Sol-Gel had $17.6 million in cash, cash equivalent, and bank deposits and $20.4 million in marketable securities for a total balance of $38.0 in comparison to December 31, 2022, of $24.9 million in cash, cash equivalent, and bank deposit and $8.7 million in marketable securities for a total balance of $33.6 million.

User Image DonCorleone77 Posted - 1 month ago

$SLGL Sol-Gel Technologies reports 2023 EPS ($1.01) vs. (65c) last year Reports 2023 revenue $1.6M vs. $3.9M last year. Alon Seri-Levy, Ph.D., Chief Executive Officer of Sol-Gel, stated: "Sol-Gel is advancing the pivotal Phase 3 clinical trial with SGT-610 in accordance with the planned timelines and expects to have the results by the end of 2025. We estimate that the current trial protocol and its defined targets may facilitate the essential outcome, allowing Sol-Gel to provide Gorlin syndrome patients with the first drug that could prevent new BCCs, with a potential market estimated at more than $300 million. Concurrently, we are pursuing additional out-license agreements similar to the agreements signed this year with Searchlight Pharma for Canada. Sol-Gel's current product portfolio, led by SGT-610 and SGT-210, positions us with substantial assets for the future."

User Image Stock_Titan Posted - 1 month ago

$SLGL Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments https://www.stocktitan.net/news/SLGL/sol-gel-reports-full-year-2023-financial-results-and-corporate-qk9r3ktyh9eh.html

User Image LoyalShark Posted - 2 months ago

$SLGL Anyone know when earnings are coming out?

User Image LoyalShark Posted - 2 months ago

Picked up shares of $VANI $QRTEA today. In $CNVS at 1.11 In $SLGL at 1.20 In $nspr at avg $2.15 - own as high as $3.50 and as low as $.98 If you have something you like on ...LIKE REALLY LIKE ... Im looking for a few "SMALL CAP ideas with an investable story and solid fundamentals.

User Image DarkSonar Posted - 2 months ago

$SLGL Please don’t run without me yet!! Let me out of these positions I’m in and I’ll join this beautiful pattern. Loving the volume present. Weekly looking like a strong fucking squeeze. 💎💎💎💎💎💎💎💎

User Image VertanosTrading Posted - 02/28/24

$SLGL I'm watching you 👁️‍🗨️

User Image ChiefOG Posted - 02/28/24

$SLGL 🧐

User Image DarkSonar Posted - 02/28/24

$SLGL Loving that fight!! Keeping this above that $1.00 mark is prime!! Loving it. Just more volume and some type of fluff and this can take off

User Image DarkSonar Posted - 02/27/24

$SLGL Finally breaking down below $1.00, keeping my eyes open for my entry. I would love to see this shoot up. Not yet. 💎💎💎💎💎💎💎💎

User Image DarkSonar Posted - 02/24/24

These are definitely the next three positions I’m leaning to start given the opportunity if they don’t run before. I’m still to confirm when I will start them as one of the most important aspects of trading isn’t completely present but in only one so far. $AIRE $SLGL $VIEWQ

User Image DarkSonar Posted - 02/24/24

$SLGL I’m liking the fight here in this area. Volume increase to keep this levels. On watch. I will keep an eye on this and wait till Earnings,.

User Image LoyalShark Posted - 02/23/24

$SLGL

User Image LoyalShark Posted - 02/14/24

$SLGL This is like a roach motel. Once you are in --- you are in forever.

User Image weichsel1 Posted - 3 months ago

$SLGL Practically no volume today at all? Average volume is just 23,000. But this is nuts..

Analyst Ratings
HC Wainwright & Co. Buy Nov 13, 23
HC Wainwright & Co. Buy Aug 14, 23
Raymond James Strong Buy Aug 11, 23
HC Wainwright & Co. Buy Jul 24, 23
Raymond James Strong Buy Jul 19, 23
HC Wainwright & Co. Buy Jun 5, 23
HC Wainwright & Co. Buy Apr 12, 23
Raymond James Strong Buy Mar 14, 23
HC Wainwright & Co. Buy Feb 1, 23